Business Description
Roivant Sciences Ltd
ISIN : BMG762791017
Share Class Description:
ROIV: Ordinary SharesTotal Employee Number:
721Compare
Compare
Traded in other countries / regions
ROIV.USA87S.Germany Index Membership
Russell 1000Russell 3000 IPO Date
2021-10-01Description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 35.86 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 47.33 | |||||
Beneish M-Score | -3.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -35.2 | |||||
3-Year EBITDA Growth Rate | -18.6 | |||||
3-Year EPS without NRI Growth Rate | -9.3 | |||||
3-Year FCF Growth Rate | 3.1 | |||||
3-Year Book Growth Rate | 60.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 35.28 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 484.78 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.05 | |||||
9-Day RSI | 78.15 | |||||
14-Day RSI | 72.54 | |||||
3-1 Month Momentum % | 27.55 | |||||
6-1 Month Momentum % | 26.27 | |||||
12-1 Month Momentum % | 181.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.72 | |||||
Quick Ratio | 16.72 | |||||
Cash Ratio | 13.55 | |||||
Days Payable | 4281.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.8 | |||||
Shareholder Yield % | 0.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.21 | |||||
Operating Margin % | -18146.12 | |||||
Net Margin % | -3534.96 | |||||
EBITDA Margin % | -18108.29 | |||||
FCF Margin % | -10901 | |||||
OCF Margin % | -10840.02 | |||||
ROE % | -6.12 | |||||
ROA % | -5.05 | |||||
ROIC % | -165.32 | |||||
3-Year ROIIC % | -94.51 | |||||
ROC (Joel Greenblatt) % | -1362.8 | |||||
ROCE % | -26.94 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3770.91 | |||||
PB Ratio | 7.08 | |||||
Price-to-Tangible-Book | 7.08 | |||||
EV-to-EBIT | -19.69 | |||||
EV-to-EBITDA | -19.74 | |||||
EV-to-Revenue | 3573.77 | |||||
EV-to-Forward-Revenue | 1855.86 | |||||
EV-to-FCF | -32.78 | |||||
Price-to-GF-Value | 5.67 | |||||
| Price-to-Net-Current-Asset-Value | 8.18 | |||||
| Price-to-Net-Cash | 10.83 | |||||
Earnings Yield (Greenblatt) % | -5.08 | |||||
FCF Yield % | -2.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ROIV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roivant Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.532 | ||
| EPS (TTM) ($) | -0.53 | ||
| Beta | 0.7256 | ||
| 3-Year Sharpe Ratio | 0.98 | ||
| 3-Year Sortino Ratio | 2.05 | ||
| Volatility % | 48.09 | ||
| 14-Day RSI | 72.54 | ||
| 14-Day ATR ($) | 1.678499 | ||
| 20-Day SMA ($) | 36.204 | ||
| 12-1 Month Momentum % | 181.49 | ||
| 52-Week Range ($) | 12.9 - 42.5 | ||
| Shares Outstanding (Mil) | 722.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roivant Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roivant Sciences Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-05 08:00 | In 150 days | ||
| Third quarter earnings results for 2027 | 2027-02-05 | In 149 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-10 08:00 | In 63 days | ||
| Second quarter earnings results for 2027 | 2026-11-10 | In 62 days | ||
| General meeting for 2026 | 2026-09-16 09:30 | In 8 days | ||
| Cantor Global Healthcare Conference | 2026-09-09 13:00 | In 1 day | ||
| Mosliciguat in PH-ILD: PHocus Study Topline Results | 2026-09-08 08:00 | 34.94 (+2.16%) | ||
| LISRAYA (brepocitinib) Approval Call | 2026-08-28 08:00 | 37.58 (+1.99%) | ||
| First quarter earnings conference call for 2027 | 2026-08-06 08:00 | 34.60 (-0.83%) | ||
| First quarter earnings results for 2027 | 2026-08-06 | 34.60 (-0.83%) |
Show
Entries
Roivant Sciences Ltd Frequently Asked Questions
What is Roivant Sciences Ltd(ROIV)'s stock price today?
The current price of ROIV is $41.48. The 52 week high of ROIV is $42.50 and 52 week low is $12.90.
When is next earnings date of Roivant Sciences Ltd(ROIV)?
The next earnings date of Roivant Sciences Ltd(ROIV) is 2026-11-10 Est..
Does Roivant Sciences Ltd(ROIV) pay dividends? If so, how much?
Roivant Sciences Ltd(ROIV) does not pay dividend.
Guru Commentaries on NAS:ROIV
Parnassus Mid Cap Growth Fund
Bullish
2026 Q2
Jerome Dodson
· 45 holdings
What the manager wrote
Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing transformative medicines, primarily in inflammation and immunology. The manager highlights Roivant's potential for growth, indicating a positive outlook for the company as it operates in a sector with significant demand for innovative therapies. The addition of Roivant to the portfolio reflects a belief in its strong growth drivers and the ability to navigate through various macroeconomic environments.
2026 Q2
What the manager wrote
New position Roivant, a biotechnology company developing therapies across a range of conditions, also supported results as investors recognized its repeatable in-licensing and drug development model. This model positions Roivant favorably in the market, as it allows for consistent innovation and potential revenue generation through strategic partnerships and acquisitions.
Press Release
Articles on Roivant Sciences Ltd
ADAR1 Capital Management, LLC Expands Tenax Therapeutics Inc (TENX) Stake in Strategic Add
13 hours ago
Roivant Sciences Ltd to Present Mosliciguat in PH-ILD: PHocus Phase 2 Study Results Transcript
1 day ago
Headlines
See More- 1
Sep 08, 2026
Roivant Sciences soars 19% on positive mosliciguat trial results
Seeking Alpha • 3:47pm
Aug 28, 2026
Pfizer-backed Priovant wins FDA approval for lead asset
Seeking Alpha • 5:48am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers